TriLink BioTechnologies社 June TriLink Messenger
|
この製品に関するご照会・お問合せはこちら
RESEARCH NEWS
|
| Lyophilized mRNA Vaccines Advance to Clinical Trials |
|
The remarkable success of the COVID-19 vaccines developed by Pfizer/BioNTech and Moderna is due to the combination of two technology platforms: mRNA vaccinology and lipid nanoparticle (LNP) delivery. Now they are taking it a step further by testing a lyophilized COVID-19 mRNA-LNP vaccine. In our most recent Zone In With Zon blog we are looking at what lyophilizing is, why it is important, and how two mRNA vaccines advance to clinical trials.
|
Dual antigen self-amplifying RNA vaccines promise enhanced protection against SARS-CoV-2
|
|
|
IL-1 and IL-1ra Regulate the Inflammatory Response to RNA Vaccines
|
|
|
A dual-antigen self-amplifying RNA vaccine has been shown to induce potent humoral and cellular immune responses that offer protection against emerging variants of SARS-CoV-2. Read on to learn more about the advantages of saRNA vaccines and why accelerating their development is important.
|
With RNA vaccines seeing increased use following successes in protecting against COVID-19, elucidating the underlying mechanisms of action is essential to maximize their potential. Read about how IL-1 and IL-1ra can regulate the inflammatory response to RNA vaccines.
|
 |
 |
|
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。
